Business Context and Reporting Period
This Form 8-K is filed by ChromaDex Corporation (not Niagen Bioscience, Inc.) on June 14, 2016. The report details the termination of a material definitive agreement regarding a loan facility.
Key Financial Metrics
The filing focuses on debt repayment rather than operational performance metrics like revenue or profit.
- Total Payoff Amount: Approximately $4,851,542
- Principal Repaid: $4,554,659
- Accrued Interest: $15,789
- End of Term Charges: $187,500
- Prepayment Penalties: $91,093
- Other Fees: $2,500
- Funding Source: Net proceeds from a registered direct offering of common stock dated June 3, 2016.
Material Changes
On June 14, 2016, ChromaDex fully satisfied and discharged all obligations under its Loan Agreement with Hercules Funding II LLC and Hercules Capital, Inc. (dated September 29, 2014). Key changes include:
- Debt Elimination: The Company repaid the aggregate principal and associated fees, terminating the loan.
- Liens Released: All first priority liens and security interests granted to Hercules on substantially all Company assets (excluding intellectual property and 35% of foreign subsidiary stock) were terminated.
- Covenants Discharged: All obligations, covenants, and liabilities under the agreement were satisfied.
- Exception: A warrant issued pursuant to the Loan Agreement remains in effect; all other documents were terminated.
Outlook, Risks, and Management Commentary
The filing does not provide forward-looking guidance, revenue outlook, or specific risk factors beyond the context of the debt termination. Management commentary is limited to the factual execution of the payoff using proceeds from the recent equity offering. The termination of the agreement removes the prepayment penalties and future interest obligations associated with this specific facility.
Investor Verification Checklist
- Verify the details of the June 3, 2016 registered direct offering to confirm the source of funds used for the payoff.
- Confirm the status of the warrant issued under the terminated Loan Agreement, as it remains outstanding.
- Review the Company's current balance sheet to confirm the removal of the $4.55 million principal liability and associated accrued interest.
- Check for any remaining covenants or obligations related to the foreign subsidiary capital stock that were excluded from the lien release.